1.50
+4.17%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About EMvision Medical Devices
Its shares trade on ASX under the ticker EMV.AX. It has been listed since 13 December 2018. In the fiscal year to 30 June 2025, it reported revenue of A$5.1m and a net loss of A$9.8m. At that date it held total assets of A$15.6m and shareholders' equity of A$9.3m.
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-12-13. The firm is engaged in the research and development of medical imaging and diagnostic technology (the EMVision Technology), for the purpose of commercializing a portable medical device for stroke diagnosis and monitoring as well as other medical imaging needs. The firm is developing and commercializing medical imaging diagnostics for various disease states and medical emergencies. The Company’s product pipeline includes portable, non-invasive, neuroimaging devices. Its lead product in development includes a portable, non-ionizing brain scanner, capable of producing images of biological tissue to provide insights for clinicians. Its second-generation device is an ultra-light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 13 Dec 2018
- Website
- emvision.com.au ↗
Leadership
Pay as last reported
- Mr. John KeepNon-Executive Chairman of the BoardA$113,667
- Mr. Scott KirklandChief Executive Officer, Managing Director, Executive Director, since 2023A$270,000
- Ms. Forough KhandanChief Technology Officer
- Ms. Emma WaldonCompany Secretary
- Ms. Carmel MonaghanNon-Executive Director
- Dr. Philip DuboisIndependent Non-Executive DirectorA$396,806
- Mr. Patryk KaniaIndependent Non-Executive Director
- Mr. Tony KeaneIndependent Non-Executive DirectorA$55,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- EMvision Medical Devices Ltd. develops portable medical imaging technology for stroke diagnosis in Sydney, Australia.
- The company's EMVision Technology enables non-invasive brain scanning for clinical insights.
- EMvision's second-generation device integrates into ambulances for pre-hospital stroke care.
Weaknesses
- EMvision's product pipeline focuses on medical imaging diagnostics with limited commercialization data.
- The company's IPO in 2018 has not yet shown significant market penetration.
- EMvision's R&D efforts are concentrated on a single medical emergency application.
Opportunities
- EMvision can expand its portable imaging technology to other medical emergencies beyond stroke.
- The Australian Health Care sector offers growth potential for non-invasive diagnostic devices.
- EMvision's technology could be adopted by international ambulance services for pre-hospital care.
Threats
- Competition in the Health Care industry may limit EMvision's market share for imaging devices.
- Regulatory hurdles in the Australian Health Care sector could delay product approvals.
- EMvision's reliance on a single product line poses a risk if technology fails.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.